Skip to content
Study details
Enrolling now

Bacteriophage Therapy Trial

Barbara Trautner
NCT IDNCT06559618ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

30

Study length

about 1.9 years

Ages

18+

Locations

2 sites in MO, TX

About this study

This trial is testing the safety of a phage treatment in adults with spinal cord injuries and bacteriuria. Participants will receive either phage therapy or a placebo for 696 days.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Placebo
  • 2.Take Phage Therapy
PhasePhase 1
Primary goalTo evaluate the safety and tolerability of phage therapy in adults ≥18 years of age with spinal cord injury (SCI) and bacteriuria with Escherichia coli (E. coli)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low11%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: To evaluate the safety and tolerability of phage therapy in adults ≥18 years of age with spinal cord injury (SCI) and bacteriuria with Escherichia coli (E. coli)

Secondary: To evaluate of the pharmacodynamics (PD) of investigational phage therapy, To evaluate the pharmacokinetics (PK) of investigational phage therapy

Body systems

Neurology